NAMS — NewAmsterdam Pharma Co N.V.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-02-08.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NAMS
| date | signal | measured base rate |
|---|---|---|
| 2026-08-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-29 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-29 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-01 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-08 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-04-29 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 70.2K | 29.96 | 2.1M |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 31.9K | 31.05 | 990.0K |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 plan | 80.0K | 11.17 | 893.6K |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 plan | 25.0K | 11.90 | 297.5K |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 2.9K | 31.71 | 92.4K |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 39.7K | 30.20 | 1.2M |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 plan | 25.0K | 10.90 | 272.5K |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 plan | 15.0K | 11.90 | 178.5K |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 300 | 30.73 | 9.2K |
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Open-market sale 10b5-1 plan | 65.0K | 35.69 | 2.3M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 542.4M | 16.9M |
| Capital World Investors | 355.6M | 11.1M |
| RA CAPITAL MANAGEMENT, L.P. | 305.7M | 9.6M |
| FCPM III SERVICES B.V. | 294.5M | 9.2M |
| FMR LLC | 280.6M | 8.8M |
| Bain Capital Life Sciences Investors, LLC | 233.9M | 7.3M |
| WELLINGTON MANAGEMENT GROUP LLP | 163.8M | 5.1M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 136.5M | 4.3M |
| VIKING GLOBAL INVESTORS LP | 134.6M | 4.2M |
| Polar Capital Holdings Plc | 90.6M | 2.8M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K/A | 2026-08-14 | 2026-07-16 | on EDGAR ↗ |
| 3 | 2026-08-14 | 2026-08-10 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-10 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-06 | — | on EDGAR ↗ |
| 8-K | 2026-08-05 | 2026-08-05 | on EDGAR ↗ |
| 10-Q | 2026-08-05 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-07-24 | 2026-07-24 | on EDGAR ↗ |
| 8-K | 2026-07-22 | 2026-07-16 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Newamsterdam Pharma Co N.V. (NAMS) filed form 8-K/A · 2026-08-14 · SEC EDGAR
- Newamsterdam Pharma Co N.V. (NAMS) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about NAMS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →